2-(2-chloro-10H-phenothiazin-10-yl)ethan-1-amine | 96018-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 2-(2-chloro-10H-phenothiazin-10-yl)ethan-1-amine
• 英文别名: 2-(2-Chlorophenothiazin-10-yl)ethanamine；2-(2-chlorophenothiazin-10-yl)ethanamine
• CAS: 96018-62-1
• 化学式: C₁₄H₁₃ClN₂S
• 分子量: 276.79
• InChiKey: IESJBDDAPAUNNN-UHFFFAOYSA-N

物化性质

• 沸点：
  445.4±45.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 2-(2-chloro-10H-phenothiazin-10-yl)ethan-1-amine 在 甲酸 作用下， 以 水 为溶剂， 反应 1.0h， 以72%的产率得到2-(2-氯吩噻嗪-10-基)-N,N-二甲基乙胺盐酸盐
  参考文献：
  名称：

  A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential

  摘要：

  Overcoming the lack of effective treatments and the continuous clinical trial failures in neurodegenerative drug discovery might require a shift from the prevailing paradigm targeting pathogenesis to the one targeting simultaneously neuroprotection and neuroregeneration. In the studies reported herein, we sought to identify small molecules that might exert neuroprotective and neuroregenerative potential as tools against neurodegenerative diseases. In doing so, we started from the reported neuroprotective/neuroregenerative mechanisms of psychotropic drugs featuring a tricyclic alkylamine scaffold. Thus, we designed a focused-chemical library of 36 entries aimed at exploring the structural requirements for efficient neuroprotective/neuroregenerative cellular activity, without the manifestation of toxicity. To this aim, we developed a synthetic protocol, which overcame the limited applicability of previously reported procedures. Next, we evaluated the synthesized compounds through a phenotypic screening pipeline, based on primary neuronal systems. Phenothiazine 2Bc showed improved neuroregenerative and neuroprotective properties with respect to reference drug desipramine (2Aa). Importantly, we have also shown that 2Bc outperformed currently available drugs in cell models of Alzheimer's and Parkinson's diseases and attenuates microglial activation by reducing iNOS expression.

  DOI：

  10.1021/acschemneuro.8b00242
• 作为产物：
  描述：

  N-[2-(2-chloro-10H-phenothiazin-10-yl)ethyl]-2,2,2-trifluoroacetamide 在 水 、 potassium carbonate 作用下， 以 甲醇 为溶剂， 以100%的产率得到2-(2-chloro-10H-phenothiazin-10-yl)ethan-1-amine
  参考文献：
  名称：

  吩噻嗪-他林异二聚体：在阿尔茨海默氏病中采用多靶点定向方法

  摘要：

  自2002年以来，没有针对阿尔茨海默氏病的临床候选药物上市。因此，迫切需要一种有效的治疗方法。我们遵循所谓的“多靶标定向配体”方法，设计了36种新型他克林-吩噻嗪异二聚体，并对其体外抗胆碱酯酶特性进行了评估。对这类衍生物的构效关系的评估突出了化合物1dC作为有效的选择性乙酰胆碱酯酶抑制剂，IC 50 = 8 nM，1aA作为有效的丁酰胆碱酯酶抑制剂，IC 50 = 15 nM。选定的杂种，即1aC，1bC，1cC，1dC和2dC表现出对τ （306-336）肽聚集的显着抑制活性，抑制百分比范围为50.5至62.1％。同样，1dC和2dC具有抑制自诱导的Aβ1–42聚集的显着能力。尽管如此，体外研究显示对HepG2细胞和小脑颗粒神经元具有细胞毒性。当以14 mg / kg（ip）对小鼠施用1dC时，未观察到病理生理异常。如体外和体内模型所示，1dC还能够渗透到CNS中。最大大脑浓度接近IC乙

  DOI：

  10.1021/acschemneuro.1c00184

文献信息

• TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
  申请人：Ohlmeyer Michael

  公开号：US20140213578A1

  公开（公告）日：2014-07-31

  Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine, dibenzoazepine and annulene and similar genera:

  本文披露了三环化学调节剂对FOXO转录因子蛋白的调节作用。这些化合物可用于治疗癌症、年龄相关蛋白质毒性、压力引起的抑郁症、炎症和痤疮。这些化合物属于以下苯硫噻嗪、二苯并氮杂环和环戊烯类似物系列：
• US9540358B2
  申请人：——

  公开号：US9540358B2

  公开（公告）日：2017-01-10
• [EN] TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：MT SINAI SCHOOL OF MEDICINE

  公开号：WO2013025882A2

  公开（公告）日：2013-02-21

  Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of phenothiazine, dibenzoazepine and annulene and similar genera.
• A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential
  作者：Elisa Uliassi、Luis Emiliano Peña-Altamira、Aixa V. Morales、Francesca Massenzio、Sabrina Petralla、Michele Rossi、Marinella Roberti、Loreto Martinez Gonzalez、Ana Martinez、Barbara Monti、Maria Laura Bolognesi

  DOI：10.1021/acschemneuro.8b00242

  日期：2019.1.16

  Overcoming the lack of effective treatments and the continuous clinical trial failures in neurodegenerative drug discovery might require a shift from the prevailing paradigm targeting pathogenesis to the one targeting simultaneously neuroprotection and neuroregeneration. In the studies reported herein, we sought to identify small molecules that might exert neuroprotective and neuroregenerative potential as tools against neurodegenerative diseases. In doing so, we started from the reported neuroprotective/neuroregenerative mechanisms of psychotropic drugs featuring a tricyclic alkylamine scaffold. Thus, we designed a focused-chemical library of 36 entries aimed at exploring the structural requirements for efficient neuroprotective/neuroregenerative cellular activity, without the manifestation of toxicity. To this aim, we developed a synthetic protocol, which overcame the limited applicability of previously reported procedures. Next, we evaluated the synthesized compounds through a phenotypic screening pipeline, based on primary neuronal systems. Phenothiazine 2Bc showed improved neuroregenerative and neuroprotective properties with respect to reference drug desipramine (2Aa). Importantly, we have also shown that 2Bc outperformed currently available drugs in cell models of Alzheimer's and Parkinson's diseases and attenuates microglial activation by reducing iNOS expression.
• Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease
  作者：Lukas Gorecki、Elisa Uliassi、Manuela Bartolini、Jana Janockova、Martina Hrabinova、Vendula Hepnarova、Lukas Prchal、Lubica Muckova、Jaroslav Pejchal、Jana Z. Karasova、Eva Mezeiova、Marketa Benkova、Tereza Kobrlova、Ondrej Soukup、Sabrina Petralla、Barbara Monti、Jan Korabecny、Maria Laura Bolognesi

  DOI：10.1021/acschemneuro.1c00184

  日期：2021.5.5

  an effective therapy is urgently needed. We followed the so-called “multitarget directed ligand” approach and designed 36 novel tacrine-phenothiazine heterodimers which were in vitro evaluated for their anticholinesterase properties. The assessment of the structure–activity relationships of such derivatives highlighted compound 1dC as a potent and selective acetylcholinesterase inhibitor with IC50

  自2002年以来，没有针对阿尔茨海默氏病的临床候选药物上市。因此，迫切需要一种有效的治疗方法。我们遵循所谓的“多靶标定向配体”方法，设计了36种新型他克林-吩噻嗪异二聚体，并对其体外抗胆碱酯酶特性进行了评估。对这类衍生物的构效关系的评估突出了化合物1dC作为有效的选择性乙酰胆碱酯酶抑制剂，IC 50 = 8 nM，1aA作为有效的丁酰胆碱酯酶抑制剂，IC 50 = 15 nM。选定的杂种，即1aC，1bC，1cC，1dC和2dC表现出对τ （306-336）肽聚集的显着抑制活性，抑制百分比范围为50.5至62.1％。同样，1dC和2dC具有抑制自诱导的Aβ1–42聚集的显着能力。尽管如此，体外研究显示对HepG2细胞和小脑颗粒神经元具有细胞毒性。当以14 mg / kg（ip）对小鼠施用1dC时，未观察到病理生理异常。如体外和体内模型所示，1dC还能够渗透到CNS中。最大大脑浓度接近IC乙